News
8h
Axios on MSNChina's biotech boom leaves U.S. playing catch-upChina is now setting the pace in life sciences R&D, conducting more clinical trials than the U.S. and licensing new ...
Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...
Western drugmakers, investors increasingly aim to acquire Chinese compounds.
TCG Labs Soleil’s Juri Biosciences is offering EpimAb Biotherapeutics up to $210 million biobucks for exclusive licensing ...
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs ...
Pharma company stocks tumbled after Donald Trump announced a plan to reduce U.S. drug prices, but regained some ground on belief the plan would be hard to implement Drug prices are expected to decline ...
On May 9, 2025, the Tianjin Municipal Administration for Market Regulation (“Tianjin AMR”) announced administrative penalties ...
At a fully automated production line in south China's Guangxi Zhuang Autonomous Region, cans of energy drinks rolled off ...
Indian CDMOs are strategically expanding through acquisitions in the US and Europe, driven by global pharma's nearshoring ...
3d
Pharmaceutical Technology on MSNChina’s CDE grants breakthrough status approval to Abbisko’s HCC therapyThe China NMPA's CDE has granted breakthrough therapy designation approval to Abbisko Therapeutics’ irpagratinib for HCC.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results